Abstract:The isolated copper(II) complex [CuL(-phen)]·HO () [HL = -HO-CHC(H)=N-CH-SH-, -phen = 1,10-phenanthroline] was structurally characterized using single-crystal X-ray crystallography. in CHCN at liquid nitrogen temperature displayed a characteristic monomeric X-band electron paramagnetic resonance spectrum having a tetragonal character with = 2.1479 and = 2.0691 and ≈ 18.0 mT and ≤ 3.9 mT, respectively. showed a strong binding affinity toward calf thymus DNA as reflected from its intrinsic binding constant ( = 7.88 × 10 M), and its competitive displacement of ethidium bromide suggested an intercalative DNA-binding mode ( = 1.32 × 10 M). This was confirmed from the viscosity study that showed an increase in the viscosity of DNA with an increasing concentration of . Complex is highly efficient in promoting oxidative and hydrolytic DNA cleavage ( = 1.987 h). showed a strong binding affinity with the carrier protein human serum albumin (HSA) ( = 5.22 × 10 M). A high bimolecular quenching constant = 2.29 × 10 Ms indicated a static quenching mechanism involved in the fluorescence quenching of HSA by . Fluorescence resonance energy transfer theory suggested that the distance ( = 3.52 nm) between and HSA is very close. Molecular docking studies suggested that primarily binds to HSA in subdomain IIA. A protein-ligand interaction profiler was used to visualize hydrophobic, hydrogen bonds, and π-cation interactions between HSA and . A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay using HeLa and MDA-MB-231 cells showed a significant in vitro anticancer activity of (IC 2.63 and 2.68 μM, respectively). Nuclear staining assays suggested apoptotic cell death in HeLa cells treated with . The effect of on the cytoskeletal actin filaments visualized using phalloidin staining showed extensive destruction of actin filaments. Flow cytometric analysis indicated that inhibits the growth of HeLa cells through cell cycle arrest in the S phase. Western blot analysis showed upregulation in the expression of apoptotic marker proteins caspase 3, p53, and Bax. These results collectively indicate that induces apoptosis by promoting DNA damage and has a high potential to act as an anticancer agent.

Design an Anticancer Copper(ii) Pro-Drug Based on the Flexible IIA Subdomain of Human Serum Albumin.

Design of an Anticancer Copper(II) Prodrug Based on the Lys199 Residue of the Active Targeting Human Serum Albumin Nanoparticle Carrier.

Developing a Copper(II) Isopropyl 2-Pyridyl Ketone Thiosemicarbazone Compound Based on the IB Subdomain of Human Serum Albumin-Indomethacin Complex: Inhibiting Tumor Growth by Remodeling the Tumor Microenvironment

Novel Brain-Tumor-Inhibiting Copper(II) Compound Based on a Human Serum Albumin (HSA)-Cell Penetrating Peptide Conjugate

Developing a Copper(II) Agent Based on His-146 and His-242 Residues of Human Serum Albumin Nanoparticles: Integration To Overcome Cisplatin Resistance and Inhibit the Metastasis of Nonsmall Cell Lung Cancer

Synthesis, structural studies, interaction with DNA/HSA and antitumor evaluation of new Cu(II) complexes containing 2-(1H-imidazol-2-yl)pyridine and amino acids

Synthesis, Characterization, DNA/HSA Interactions, and Anticancer Activity of Two Novel Copper(II) Complexes with 4-Chloro-3-Nitrobenzoic Acid Ligand

Anticancer potential of Cu(II)prolinedithiocarbamate complex: design, synthesis, spectroscopy, molecular docking, molecular dynamic, ADMET, and in-vitro studies

Designing metal chelates of halogenated sulfonamide Schiff bases as potent nonplatinum anticancer drugs using spectroscopic, molecular docking and biological studies

Synthesis, characterization and biological activity of novel copper complexes containing a β-carboline derivative and amino acids

Mixed Ligand Mononuclear Copper(II) Complex as a Promising Anticancer Agent: Interaction Studies with DNA/HSA, Molecular Docking, and In Vitro Cytotoxicity Studies.

Developing a Palladium(II) Agent to Overcome Multidrug Resistance and Metastasis of Liver Tumor by Targeted Multiacting on Tumor Cell, Inactivating Cancer-Associated Fibroblast and Activating Immune Response

Square pyramidal Cu(II) Acylpyrazolone Complex: Synthesis, Characterization, Crystal structure, DFT and Hirshfeld analysis, in-vitro anti-cancer evaluation

Cytotoxic palladium(II) complexes of 8-aminoquinoline derivatives and the interaction with human serum albumin.

Thiazole Functionalization of Thiosemicarbazone for Cu(II) Complexation: Moving toward Highly Efficient Anticancer Drugs with Promising Oral Bioavailability

Designing biotin-human serum albumin nanoparticles to enhance the targeting ability of binuclear ruthenium(III) compound

Design, Synthesis, and biological evaluation of copper(II) complexes with phenanthroline-based ligands as potential anticancer agents

Design, Synthesis, and Anti-Cancer Evaluation of Novel Water-Soluble Copper(I) Complexes Bearing Terpyridine and PTA Ligands

Cell-penetrating peptide-conjugated copper complexes for redox-mediated anticancer therapy

Polypeptide-Based Copper Ionophore for In Situ Glutathione-Triggered Chemodynamic and Chemotherapy

Human Serum Albumin-Based Dual-Agent Delivery Systems for Combination Therapy: Acting against Cancer Cells and Inhibiting Neovascularization in the Tumor Microenvironment